---
title: 'Manager, CMC Project Management at Crescent Biopharma'
canonical: 'https://feeny.ai/job/manager-cmc-project-management-crescent-biopharma-waltham-bad0nec61tqz'
type: 'job'
last_seen: '2026-10-15'
---

# Manager, CMC Project Management at Crescent Biopharma

- **Company:** Crescent Biopharma
- **Location:** Waltham, MA
- **Compensation:** $140k–$180k
- **Employment:** full-time
- **Work type:** onsite
- **Posted:** 2026-07-21
- **Last confirmed live:** 2026-10-15
- **Apply:** https://jobs.lever.co/crescent-biopharma/937d7c2f-16c2-4605-8837-197b4b4c837c

## Job description

Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company’s clinical-stage pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates. By leveraging multiple modalities and established targets, Crescent aims to rapidly advance potentially transformative therapies as single agents and as part of combination regimens to treat a range of solid tumors. For more information, visit www.crescentbiopharma.com and follow the Company on LinkedIn and X.

We are seeking a Manager, CMC Project Management who is responsible for driving cross-functional execution of CMC activities in support of early and late-stage clinical development programs. Working closely with Technical Operations  - including Drug Substance, Drug Product, Analytical Development, Regulatory CMC, Quality, Supply Chain and external partners, this role leads integrated project planning, facilitates cross-functional alignment, manages risks and timelines, and enables successful delivery of CMC milestones in support of regulatory and development objectives. This role is based in Waltham, MA and you must have experience in the oncology space.

## Responsibilities

- Lead cross-functional CMC project management for clinical-stage development programs, developing and maintaining integrated project plans, timelines, critical path activities, milestones, risks, and decision logs.
- Drive project execution by facilitating cross-functional meetings, tracking actions and decisions, proactively identifying risks and dependencies, and escalating issues to ensure program objectives are achieved.
- Coordinate activities across Drug Substance, Drug Product, Analytical Development, Quality Control, Quality Assurance, Supply Chain, Regulatory CMC, and other Technical Operations functions to ensure alignment of priorities and deliverables
- Partner with CDMOs, CROs, testing laboratories, and other external vendors to monitor deliverables, manufacturing activities, timelines, and issue resolution.
- Coordinate planning and execution of CMC regulatory submissions, including INDs, IMPDs, amendments, and health authority responses, ensuring cross-functional deliverables are completed on schedule.
- Support program budgeting, forecasting, resource planning, purchase order tracking, and financial reporting to enable effective execution of CMC development activities.
- Identify and implement process improvements to strengthen CMC project execution, governance, resource planning, and organizational effectiveness.

Education & Experience

- Bachelor’s degree in a scientific, engineering, or related discipline required.
- 5–8 years of biotech or pharmaceutical industry experience.
- Experience in CMC, Technical Operations, Project Management, Manufacturing, Supply Chain, or related functions.
- Familiarity with GMP manufacturing and external partner management.
- Strong project management and organizational skills.
- Ability to manage multiple priorities in a fast-paced environment.
- Excellent communication and collaboration skills.
- Experience with project planning and tracking tools.
- Ability to identify risks and drive issue resolution.
- Detail-oriented with strong follow-through and accountability

## What We Offer

- Opportunity to join a mission-driven team where you'll contribute to impactful work, take on varied responsibilities, and grow quickly in a dynamic environment
- Competitive compensation, including base salary, performance bonus, and equity
- 100% employer-paid benefits package
- Flexible PTO; also, two, one-week company-wide shutdowns each year
- A commitment to your professional development, with access to resources, mentorship, and growth opportunities

## About Crescent Biopharma

## Company Overview
- **One-liner**: Crescent Biopharma is a clinical-stage oncology company developing next-wave cancer therapies, including a PD-1 x VEGF bispecific antibody and antibody-drug conjugates (ADCs) for solid tumors.
- **Entity Type**: Public (IPO in June 2025; ticker not disclosed in available data)
- **Headquarters**: Waltham, Massachusetts, United States (300 Fifth Avenue, Waltham, MA 02451)
- **Founded**: Year not publicly available (company appears to have been active before 2024; IPO in 2025)
- **Founders**: Not publicly available (leadership includes CEO Joshua Brumm, but founder information is not listed)

## Core Business
- **Primary industry/industries**: Oncology biotechnology / Therapeutics
- **Target customers**: B2B – primarily focuses on developing and commercializing cancer therapies, with partnerships and collaborations (e.g., Kelun-Biotech, Paragon Therapeutics)
- **Mission or purpose statement**: “Delivering the next wave of transformative therapies to bring a brighter future for people living with cancer.”

## Products & Services
- **CR-001 (PD-1 x VEGF bispecific antibody)**: A tetravalent bispecific antibody in Phase 1/2 clinical trials (ASCEND) for advanced solid tumors. Designed to exhibit cooperative pharmacology similar to ivonescimab; aims to restore T-cell activity and localize anti-VEGF activity in the tumor microenvironment. Collaboration with Kelun-Biotech for Greater China rights.
- **CR-002 (PD-L1–directed ADC)**: A topoisomerase inhibitor ADC targeting PD-L1, with high internalization. IND planned for mid-2026, with Phase 1/2 trial expected in H2 2026.
- **CR-003 (ITGB6–directed ADC)**: A differentiated ADC targeting integrin beta-6 (ITGB6), with a topoisomerase 1 inhibitor payload. Uses Kthiol conjugation technology. Licensed from Kelun-Biotech for ex-Greater China markets; Phase 1/2 trial ongoing in China.

## Market Standing
- **Valuation/Market Cap**: Not disclosed (public company as of 2025, but no valuation or market cap figure available in provided data)
- **Key Metric**: Total Funding: $585M (including $200M Series A in 2024, $185M Post-IPO Equity in 2025, and $200M Post-IPO Equity in 2025 led by Fairmount Funds Management)
- **Notable Investors/Partners**: Fairmount Funds Management, Venrock Healthcare Capital Partners, Kelun-Biotech (strategic collaboration), Paragon Therapeutics
- **Growth Signals**: Headcount grew 129.6% YoY to 55 employees (LinkedIn); IPO in June 2025; multiple pipeline programs advancing toward IND; expansion into ADC combination trials

## Competitive Advantages
- Focus on established, clinically validated targets (PD-1, VEGF, PD-L1, ITGB6) to reduce risk and accelerate development
- Multi-modality approach (bispecific antibodies + ADCs) enabling combination therapies with potential synergistic effects
- Proprietary ADC technology (Kthiol conjugation) and strategic collaborations for global rights to differentiated assets
- Strong leadership team with deep oncology drug development expertise (former executives from major biopharma)

## Strategic Focus
- Advance CR-001 as a foundational backbone therapy, with initiation of combination trials with ADCs in H2 2026
- Submit IND for CR-002 in mid-2026 and begin Phase 1/2 trials
- Progress CR-003 clinical program and explore additional internal and partnered ADC and immuno-oncology opportunities
- Build a leading oncology company through disciplined execution, leveraging established biology and multiple modalities

## Why Work Here
- **Culture highlights**: “No egos, collaborative spirit,” “roll up sleeves,” “move with urgency,” “data-driven science with patients as true north.” Emphasizes transparency, integrity, and impact.
- **Remote/hybrid/office policy**: Not explicitly stated; headquarters in Waltham, MA, with an office in Rockville, MD. Likely requires on-site presence given the “highly collaborative” and “urgent” culture.
- **Notable perks**: 100% employer-paid medical, dental, vision, short/long-term disability, life insurance; HSA and dependent care FSA; 401(k); subsidized lunch program; flexible vacation and paid holidays including summer and year-end office closures (one week each).
- **Best for**: Bold innovators who want to make a significant impact in oncology drug development, thrive in a fast-paced, transparent environment, and are motivated by patient outcomes.

## Sources
1. [crescentbiopharma.com – Careers](https://www.crescentbiopharma.com/careers/)
2. [crescentbiopharma.com – About](https://www.crescentbiopharma.com/about/)
3. [crescentbiopharma.com – Pipeline](https://www.crescentbiopharma.com/pipeline/)
4. [linkedin.com – Crescent Biopharma](https://www.linkedin.com/company/crescent-biopharma)
5. [jobs.lever.co – Crescent Biopharma](https://jobs.lever.co/crescent-biopharma)

## Other roles at Crescent Biopharma

- [Director, Talent Acquisition](https://feeny.ai/job/director-talent-acquisition-crescent-biopharma-waltham-baae5mra4znc) — Waltham, MA
- [Executive Director/Vice President, Corporate Development](https://feeny.ai/job/executive-director-vice-president-corporate-development-crescent-biopharma-a167et02k0jt) — Waltham, MA
- [Director, ADC Drug Substance](https://feeny.ai/job/director-adc-drug-substance-crescent-biopharma-waltham-7dyxva49nmt1) — Waltham, MA
- [Director/Senior Director, Drug Product](https://feeny.ai/job/director-senior-director-drug-product-crescent-biopharma-waltham-pj5x6ve5sp22) — Waltham, MA
- [Executive Assistant - R&D](https://feeny.ai/job/executive-assistant-r-d-crescent-biopharma-waltham-th1vr004bn6z) — Waltham, MA
- [Director/Senior Director, GMP Quality Assurance Operations](https://feeny.ai/job/director-senior-director-gmp-quality-assurance-operations-crescent-biopharma-zt813qk13fnp) — Waltham, MA
- [Director/Senior Director, QMS, Digital QA and GxP Compliance](https://feeny.ai/job/director-senior-director-qms-digital-qa-and-gxp-compliance-crescent-biopharma-brmrgq5qf5xc) — Waltham, MA
- [Vice President, Pharmacovigilance](https://feeny.ai/job/vice-president-pharmacovigilance-crescent-biopharma-waltham-47ss86sacfsv) — Waltham, MA
- [Vice President, Program Team Leader](https://feeny.ai/job/vice-president-program-team-leader-crescent-biopharma-waltham-326643dkvpjm) — Waltham, MA
- [Executive Director, Regulatory Affairs CMC](https://feeny.ai/job/executive-director-regulatory-affairs-cmc-crescent-biopharma-waltham-m0e9ryfqjqmg) — Waltham, MA